| A new type of synthetic peptide library for identifying ligand-binding activity KS Lam, SE Salmon, EM Hersh, VJ Hruby, WM Kazmierski, RJ Knapp Nature 354 (6348), 82-84, 1991 | 2719 | 1991 |
| Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. VJ Hruby, F al-Obeidi, W Kazmierski Biochemical journal 268 (2), 249, 1990 | 742 | 1990 |
| The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor C Watson, S Jenkinson, W Kazmierski, T Kenakin Molecular pharmacology 67 (4), 1268-1282, 2005 | 362 | 2005 |
| Design and synthesis of conformationally constrained somatostatin analogs with high potency and specificity for. mu. opioid receptors JT Pelton, W Kazmierski, K Gulya, HI Yamamura, VJ Hruby Journal of medicinal chemistry 29 (11), 2370-2375, 1986 | 254 | 1986 |
| Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo. TH Kramer, JE Shook, W Kazmierski, EA Ayres, WS Wire, VJ Hruby, ... Journal of Pharmacology and Experimental Therapeutics 249 (2), 544-551, 1989 | 176 | 1989 |
| Design and synthesis of somatostatin analogs with topographical properties that lead to highly potent and specific. mu. opioid receptor antagonists with greatly reduced binding … W Kazmierski, WS Wire, GK Lui, RJ Knapp, JE Shook, TF Burks, ... Journal of medicinal chemistry 31 (11), 2170-2177, 1988 | 165 | 1988 |
| Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors W Kazmierski, N Bifulco, H Yang, L Boone, F DeAnda, C Watson, ... Bioorganic & medicinal chemistry 11 (13), 2663-2676, 2003 | 157 | 2003 |
| N-(2-Benzoylphenyl)-l-tyrosine PPARγ Agonists. 2. Structure−Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety JL Collins, SG Blanchard, GE Boswell, PS Charifson, JE Cobb, BR Henke, ... Journal of Medicinal Chemistry 41 (25), 5037-5054, 1998 | 152 | 1998 |
| [3H]-[HD-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2]([3H] CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain. KN Hawkins, RJ Knapp, GK Lui, K Gulya, W Kazmierski, YP Wan, ... Journal of Pharmacology and Experimental Therapeutics 248 (1), 73-80, 1989 | 136 | 1989 |
| Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity WM Kazmierski, HI Yamamura, VJ Hruby Journal of the American Chemical Society 113 (6), 2275-2283, 1991 | 135 | 1991 |
| A new approach to receptor ligand design: synthesis and conformation of a new class of potent and highly selective μ opioid antagonists utilizing tetrahydroisoouinoline … W Kazmierski, VJ Hruby Tetrahedron 44 (3), 697-710, 1988 | 126 | 1988 |
| The chemical synthesis of large random peptide libraries and their use for the discovery of ligands for macromolecular acceptors KS Lam, VJ Hruby, M Lebl, RJ Knapp, WM Kazmierski, EM Hersh, ... Bioorganic & Medicinal Chemistry Letters 3 (3), 419-424, 1993 | 120 | 1993 |
| Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds A Spaltenstein, MR Almond, WJ Bock, DG Cleary, ES Furfine, RJ Hazen, ... Bioorganic & medicinal chemistry letters 10 (11), 1159-1162, 2000 | 93 | 2000 |
| The relative activity of “function sparing” HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? VM Muniz-Medina, S Jones, JM Maglich, C Galardi, RE Hollingsworth, ... Molecular Pharmacology 75 (3), 490-501, 2009 | 81 | 2009 |
| Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties WM Kazmierski, W Andrews, E Furfine, A Spaltenstein, L Wright Bioorganic & medicinal chemistry letters 14 (22), 5689-5692, 2004 | 75 | 2004 |
| Peptide, Peptidomimetic and Small‐molecule Drug Discovery Targeting HIV‐1 Host‐cell Attachment and Entry through gp120, gp41, CCR5 and CXCR4† WM Kazmierski, TP Kenakin, KS Gudmundsson Chemical biology & drug design 67 (1), 13-26, 2006 | 67 | 2006 |
| Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties X Li, S Zhang, YK Zhang, Y Liu, CZ Ding, Y Zhou, JJ Plattner, SJ Baker, ... Bioorganic & medicinal chemistry letters 21 (7), 2048-2054, 2011 | 61 | 2011 |
| Opioid receptor selectivity of beta-endorphin in vitro and in vivo: mu, delta and epsilon receptors. JE Shook, W Kazmierski, WS Wire, PK Lemcke, VJ Hruby, TF Burks Journal of Pharmacology and Experimental Therapeutics 246 (3), 1018-1025, 1988 | 61 | 1988 |
| Targeting the NS5A protein of HCV: an emerging option DG Cordek, JT Bechtel, AT Maynard, WM Kazmierski, CE Cameron Drugs of the Future 36 (9), 691, 2011 | 60 | 2011 |
| Synthesis and evaluation of novel α-amino cyclic boronates as inhibitors of HCV NS3 protease X Li, YK Zhang, Y Liu, CZ Ding, Q Li, Y Zhou, JJ Plattner, SJ Baker, X Qian, ... Bioorganic & medicinal chemistry letters 20 (12), 3550-3556, 2010 | 59 | 2010 |
